MRPL32

Across TCGA pan-cancer cohorts, MRPL32 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MRPL32 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MRPL32 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL32 expression acts as an unfavorable survival marker.

BRCA, SARC, and UCEC are the cancer types where MRPL32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.191	0.924	<.001	30	view →
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MRPL32–BRCA (OS)

Open the BRCA breakdown →